Equillium, Inc.

130 articles about Equillium, Inc.

• Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association

  5/12/2022

  Equillium, Inc. announced that the European Hematology Association has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease.

• Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates

  5/12/2022

  Equillium, Inc. announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.

• 

  BioSpace Speaks with R&D Leaders for World Lupus Day

  5/10/2022

  In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.

• Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists

  5/9/2022

  Equillium, Inc. today announced that three posters were presented over the weekend at IMMUNOLOGY2022, the annual meeting of The American Association of Immunologists.

• Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR

  4/25/2022

  Equillium, Inc. today announced that three posters were presented over the weekend at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.

• Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology

  4/4/2022

  Equillium, Inc. announced an oral presentation at the 2022 National Congress of the Italian Society of Experimental Hematology in Rome, Italy.

• Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates

  3/23/2022

  Equillium, Inc. announced financial results for the fourth quarter and full year 2021 and provided corporate and clinical development updates.

• Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation

  3/23/2022

  Equillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, announced two oral presentations at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation.

• Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

  3/4/2022

  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the initiation of the EQUATOR study, a pivotal Phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease (aGVHD).

• Equillium Announces Appointment of Barbara Troupin to Board of Directors

  3/1/2022

  Equillium, Inc. today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors.

• Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates

  2/16/2022

  Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform.

• Equillium Provides Timing Update on Conference Presentations

  2/15/2022

  Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, announced timing updates for two separate conference presentations.

• Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference

  2/9/2022

  Equillium, Inc. announced that it will participate in a fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference, taking place February 14 – 18, 2022.

• Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR

  1/10/2022

  Equillium, Inc. announced that three abstracts were accepted for presentation at the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.

• Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference - Jan 05, 2022

  1/5/2022

  Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference.

• Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis

  1/4/2022

  Equillium, Inc. (Nasdaq: EQ), today announced publication of a manuscript featured on the front cover of the Journal of Clinical Investigation (www.jci.org/this-month), confirming the role of T cells activated by the CD6-ALCAM pathway in the development of lupus nephritis (LN).

• Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma

  1/4/2022

  Equillium, Inc. (Nasdaq: EQ), today announced that the Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective of safety and tolerability and demonstrated on-target peak and sustained reduction of CD6 at Day 85 (one month following last dose).

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab

  12/13/2021

  Equillium, Inc. today announced two poster presentations at the 63rd Annual Meeting of the American Society of Hematology.

• Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates

  11/10/2021

  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2021, and provided an update on its clinical programs.